BioXpress Therapeutics, known for developing monoclonal antibody biosimilars, has entered into a partnership with contract development and manufacturing organization Abzena – that provides patient solutions for biologics and bioconjugates – to support biosimilar development for third party customers.
According to the companies, the partnership “creates an integrated solution between two service providers with expertise in biosimilar development and...






